

(English version)

**Question for written answer E-004953/25  
to the Commission  
Paolo Inselvini (ECR), Carlo Fidanza (ECR)  
(15 December 2025)**

*Subject:* EU procurement for stocks of antigens, vaccines and diagnostic reagents against animal lumpy skin disease (LSD)

Lumpy Skin Disease is classified as an animal disease (mainly bovine) of Group A in accordance with Delegated Regulation (EU) 2018/1629 <sup>(1)</sup> supplementing Regulation (EU) 2016/429 <sup>(2)</sup>. This classification requires immediate eradication/control measures to be taken by Member States and allows the Commission to establish EU stocks of antigens-vaccines and diagnostic reagents.

Articles 48 to 49 of Regulation (EU) 2016/429 empower the Commission to establish, manage, renew and make available EU stocks for listed diseases. Implementing Regulation (EU) 2022/140 <sup>(3)</sup> also regulates the associated operational measures: supply, replacement, management and distribution.

The epidemiological evolution of LSD in the Member States, including Italy, highlights the importance of ensuring timely availability of vaccines/diagnostic materials, including with regard to the EU stock replacement/renewal needs provided for in the legislation.

In view of the above:

1. Can the Commission say when it intends to launch and publish a new EU tender procedure for the procurement of antigens, vaccines and diagnostic reagents against LSD, under Articles 48 to 49 of Regulation (EU) 2016/429?
2. What transitional measures are currently available/actionable to provide support to Member States should this be required at a time when EU stocks need to be replaced/renewed/supplemented?
3. How is the Commission ensuring that the epidemiological evolution of LSD is being adequately taken into account in the planning, scaling and renewal of EU stocks for that disease?

Submitted: 15.12.2025

**Answer given by Mr Várhelyi on behalf of the European Commission  
(9 March 2026)**

The Commission invites the Honourable Member to refer to the answer to P-004548/2025/rev1 <sup>(1)</sup>. As set out therein, procurement actions to replenish the EU Lumpy Skin Disease (LSD) vaccine bank are planned <sup>(2)</sup>, and the relevant EU tender procedure will be launched and published without delay.

To note that the current planning for the new EU LSD vaccine bank goes well beyond the minimum capacity, as laid down in Commission Implementing Regulation (EU) 2022/140 <sup>(3)</sup>, to address possible contingencies, considering the current epidemiological situation and to further support the Member States.

A high level of preparedness for animal diseases, including vaccination capacity and/or procurement procedures, remains essential for effective prevention and control, and Member States should ensure that appropriate arrangements are in place at national level.

The Commission closely monitors the epidemiological evolution of LSD. As outlined in the above reply to P-4548/2025/rev1, the three currently affected Member States, France, Italy, and Spain, were already supported through the delivery of vaccine doses from the Union vaccine bank, enabling the rapid initiation of vaccination in restricted zones.

---

<sup>1</sup> [https://eur-lex.europa.eu/eli/reg\\_del/2018/1629/oj/eng](https://eur-lex.europa.eu/eli/reg_del/2018/1629/oj/eng).

<sup>2</sup> <https://eur-lex.europa.eu/eli/reg/2016/429/oj/eng>.

<sup>3</sup> [https://eur-lex.europa.eu/eli/reg\\_impl/2022/140/oj/eng](https://eur-lex.europa.eu/eli/reg_impl/2022/140/oj/eng).

<sup>(1)</sup> [https://www.europarl.europa.eu/doceo/document/P-10-2025-004548\\_EN.html](https://www.europarl.europa.eu/doceo/document/P-10-2025-004548_EN.html).

<sup>(2)</sup> <https://ted.europa.eu/en/notice/-/detail/853479-2025>;

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/tender-details/f907334f-f502-4518-8284-73639b0524bd-PIN>.

<sup>(3)</sup> [http://data.europa.eu/eli/reg\\_impl/2022/140/oj](http://data.europa.eu/eli/reg_impl/2022/140/oj).